Daily Briefing

5 minute read

Supreme Court divided on cancer warning labels in Roundup lawsuit


The U.S. Supreme Court recently heard arguments in a case on how to label health risks associated with the popular pesticide Roundup, with the decision potentially impacting thousands of lawsuits alleging that the product causes cancer. 

Supreme Court considers case over Roundup cancer claims

In the 1970s, Monsanto developed the pesticide Roundup, which became a popular weedkiller. However, there has been a growing number of claims that glyphosate, a key ingredient in Roundup, potentially causes cancer. Currently, roughly 200,000 claims have been made against Roundup, with over 125,000 since 2015.

Bayer, which acquired Monsanto in 2018, has disputed the cancer claims associated with Roundup, but the company has set aside $16 billion to settle cases related to the pesticide. Bayer has also removed glyphosate in Roundup sold in the U.S. residential lawn and garden market, but the ingredient is still included in Roundup sold to farmers and businesses.

Earlier this year, Bayer agreed to a proposed settlement of $7.25 billion to resolve thousands of lawsuits related to Roundup. Under the proposed settlement, Bayer would make annual payments into a special fund for up to 21 years for as much as $7.25 billion.

So far, the proposed settlement has been submitted to a Missouri circuit court judge for approval, but it is not guaranteed to go through. In 2020, a $10 billion settlement was thrown out after a judge objected to how future claims would be handled. 

The U.S. Supreme Court also recently heard arguments related to thousands of Roundup lawsuits. Specifically, the case focuses on warning labels about potential health risks associated with pesticides and whether states have the power to require companies to add them.

According to Bayer, the Environmental Protection Agency (EPA) approved a label without a cancer warning, so it should be required to follow federal standards instead of the state's laws or rulings that plaintiffs have sued under.

Sarah Harris, U.S. principal deputy solicitor general, backed Bayer in the case and argued EPA has authority over warning labels for pesticides rather than specific states.

Certain states may require "adding cancer warnings but federal law requires EPA to approve new warnings and tasks EPA with deciding what label changes would mitigate any health risks," Harris said. "State law must give way."

 

 

"This is the first time we have been able to link pesticide exposure, on a national scale, to biological changes suggesting an increased risk of cancer."

Currently, the justices appear to be divided over the case, with some agreeing with Bayer that there needs to be a single, uniform standard for warning labels while others questioned what would happen if the federal government moved more slowly than states in response to new dangers or research. Currently, EPA only reviews its labeling determinations every 15 years.

"There's a 15-year window between when that product has to be re-registered again and lots of things can happen in science, in terms of development about the product," Justice Ketanji Brown Jackson said. 

Although states determining warning labels for pesticides "does undermine the uniformity, … [i]f it turns out they were right, it might have been good if they had an opportunity to do something, to call this danger to the attention of people while the federal government was going through its process," Chief Justice John Roberts said.

Depending on how the justices rule, thousands of ongoing Roundup lawsuits could be blocked. A ruling on the case is expected by the end of June or early July. 

The potential link between pesticides and cancer

Currently, the potential link between pesticides and cancer is unclear. Although EPA has determined that glyphosate is not likely to be carcinogenic to humans when used as directed, the World Health Organization has classified the chemical as "probably carcinogenic."

Recent research also suggests that pesticides may increase the risk of cancer. For example, a study published in Nature Health also found a strong association between environmental exposure to agricultural pesticides and an increased risk of cancer. For the study, researchers created detailed models to show how agricultural chemicals, including 31 common pesticides, were used across Peru and compared them to health data from over 150,000 cancer patients collected from 2007 and 2020.

Overall, the researchers found that regions with higher exposure to environmental pesticides had higher rates of certain cancers. In these areas, the likelihood of developing cancer was roughly 150% higher on average.

"This is the first time we have been able to link pesticide exposure, on a national scale, to biological changes suggesting an increased risk of cancer," said Stéphane Bertani, a researcher in molecular biology at the French National Research Institute for Sustainable Development.

A separate study presented at the annual meeting of the American Association for Cancer Research found that young people who had a diet rich in fruits and vegetables had a higher risk of lung cancer, which researchers suggested could be a result of pesticides sprayed on the foods.

According to Jorge Nieva, a medical oncologist and lung cancer specialist at USC Norris Comprehensive Cancer Center and lead author of the study, commercially produced, nonorganic fruits, vegetables, and whole grains are more likely to be associated with a higher pesticide residue than dairy, meat, and many processed foods. Nieva also noted that agricultural workers exposed to pesticides typically have higher rates of lung cancer.

In response, Marc Siegel, a clinical professor of medicine at NYU Langone Medical Center, said the study is "interesting" but added that it "raises far more questions than it answers."

"It is possible that the increased lung cancer risk could be due to pesticide exposure in whole farmed foods, but it is by no means certain," he said. "How much exposure is needed? How much of it gets into food and in which areas? This requires much further study."

(Associated Press/STAT, 4/27; VanSickle, New York Times, 4/27; Johnson, NPR, 4/27; Science Daily, 4/27; Srivastava, Healthandme, 4/29)


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.